Neonate characteristics after maternal use of antidepressants in late pregnancy - PubMed (original) (raw)

Neonate characteristics after maternal use of antidepressants in late pregnancy

Bengt Källén. Arch Pediatr Adolesc Med. 2004 Apr.

Abstract

Background: Exposure to antidepressants during the third trimester of pregnancy has been associated with an increased risk for adverse birth outcomes, including preterm birth, respiratory distress, and hypoglycemia.

Objective: To investigate neonatal outcomes in 997 infants (987 mothers) after maternal use of antidepressants based on prospectively recorded information in antenatal care documents.

Results: An increased risk for preterm birth (odds ratio [OR], 1.96) and low birth weight (OR, 1.98) was verified, but the gestational week-specific birth weight was increased notably after exposure to tricyclic antidepressants. An increased risk for a low Apgar score (OR, 2.33), respiratory distress (OR, 2.21), neonatal convulsions (OR,1.90), and hypoglycemia (OR, 1.62) was found, the latter especially after exposure to tricyclic drugs, but no significant effect on the frequency of neonatal jaundice was seen (OR, 1.13). Most effects seemed not to be selective serotonin reuptake inhibitor drug specific, and outcomes after exposure to paroxetine hydrochloride were not worse than after exposure to other selective serotonin reuptake inhibitors.

Conclusions: Neonatal effects after maternal use of antidepressant drugs during late pregnancy were seen. Selective serotonin reuptake inhibitors may be the drugs of choice during pregnancy.

PubMed Disclaimer

Comment in

Discontinuation syndrome following late pregnancy exposure to antidepressants.
Koren G. Koren G. Arch Pediatr Adolesc Med. 2004 Apr;158(4):307-8. doi: 10.1001/archpedi.158.4.307. Arch Pediatr Adolesc Med. 2004. PMID: 15066865 No abstract available.

Cited by

Timing of selective serotonin reuptake inhibitor use and risk for preterm birth and related adverse events: with a consideration of the COVID-19 pandemic period.
Hwang YM, Roper RT, Piekos SN, Enquobahrie DA, Hebert MF, Paquette AG, Baloni P, Price ND, Hood L, Hadlock JJ. Hwang YM, et al. J Matern Fetal Neonatal Med. 2024 Dec;37(1):2313364. doi: 10.1080/14767058.2024.2313364. Epub 2024 Feb 11. J Matern Fetal Neonatal Med. 2024. PMID: 38342572
Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation.
Avachat C, Younis IR, Birnbaum AK. Avachat C, et al. Clin Pharmacol Ther. 2023 Dec;114(6):1238-1242. doi: 10.1002/cpt.3059. Epub 2023 Oct 13. Clin Pharmacol Ther. 2023. PMID: 37750407
Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders.
Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere AF, Vecchio S, Pistelli A, Mangili G, Bondi E, Somaini L, Gallo M, Balestrieri M, Albert U. Eleftheriou G, et al. Int J Environ Res Public Health. 2023 Aug 11;20(16):6565. doi: 10.3390/ijerph20166565. Int J Environ Res Public Health. 2023. PMID: 37623151 Free PMC article.
Psychiatric disorders during pregnancy in asymptomatic and mildly symptomatic SARS-CoV-2 positive women: Prevalence and effect on outcome.
Abulseoud OA, Chan B, Rivera-Chiauzzi EY, Egol CJ, Nettey VN, Van Ligten MJ, Griffin TN, Aly M, Sinha S, Schneekloth TD. Abulseoud OA, et al. Psychiatry Res. 2023 Aug;326:115313. doi: 10.1016/j.psychres.2023.115313. Epub 2023 Jun 16. Psychiatry Res. 2023. PMID: 37336168 Free PMC article.
The Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review.
Uguz F. Uguz F. Alpha Psychiatry. 2021 Sep 1;22(5):224-229. doi: 10.1530/alphapsychiatry.2021.21143. eCollection 2021 Sep. Alpha Psychiatry. 2021. PMID: 36447450 Free PMC article. Review.

Neonate characteristics after maternal use of antidepressants in late pregnancy - PubMed (original) (raw)